COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods

Author:

Marofi Faroogh1,Azizi Ramyar2,Motavalli Roza3,Vahedi Ghasem4,Nasimi Maryam5,Yousefi Mehdi6,Motavalli Yalda7,Tahmasebi Safa8,Gharibi Tohid6,Mohammed Rebar N.9,Etemadi Jalal10,Khiavi Farhad M.11ORCID

Affiliation:

1. Department of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

2. Nursing Department, Mahabad Branch, Islamic Azad University, Mahabad, Iran

3. Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

4. Department of Immunology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

5. Associate Professor of Dermatology, Tehran University of Medical Sciences, Tehran, Iran

6. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

7. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

8. Department of Immunology, Health Faculty, Tehran University of Medical Sciences, Tehran, Iran

9. Department of Microbiology, College of Veterinary Medicine, University of Sulaimani, Sulaimani, Iraq

10. Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

11. Department of Virology, Pasteur Institute of Iran, Tehran, Iran

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) firstly emerged in Wuhan, China at the end of 2019. After going through the experimental process, the virus was named the novel coronavirus (2019-nCoV) by the World Health Organization (WHO) in February 2020 which has created a global pandemic. The coronavirus disease 2019 (COVID-19) infection is challenging the people who are especially suffering from chronic health problems such as asthma, diabetes, and heart disease or immune system deteriorating disorders, including cancers, Alzheimer's, etc. Other predisposing/risk factors consist of smoking and age (elderly people are at higher risk). The 2019-nCoV attacks epithelial cells in all organs, particularly epithelial cells in the lungs, resulting in viral pneumonia. The 2019-nCoV starts its invasion with the attachment and entry into the respiratory tract epithelial cells via Angiotensin-Converting Enzyme 2 (ACE2) receptors on the epithelial cells. The critical problem with 2019-nCoV is its ability in human to human asymptomatic transmission which causes the rapid and hidden spread of the virus among the population. Also, there are several reports of highly variable and tightly case-dependent clinical manifestations caused by SARS-CoV2, which made the virus more enigmatic. The clinical symptoms are varied from common manifestations which occurred in flu and cold, such as cough, fever, body-ache, trembling, and runny nose to severe conditions, like the Acute Respiratory Distress Syndrome (ARDS) or even uncommon/unusual symptoms such as anosmia, skin color change, and stroke. In fact, besides serious injuries in the respiratory system, COVID-19 invades and damages various organs, including the kidney, liver, gastrointestinal, and nervous system. Accordingly, to cut the transmission chain of disease and control the infection spread. One of the major solutions seems to be early detection of the carriers, particularly the asymptomatic people, with sensitive and accurate diagnostic techniques. Moreover, developing novel and appropriate therapeutic approaches will contribute to the suitable management of the pandemic. Therefore, there is an urgent necessity to make comprehensive investigations and study reviews about COVID-19, offering the latest findings of novel therapies, drugs, epidemiology, and routes of virus transmission and pathogenesis. In this review, we discuss new therapeutic outcomes and cover and the most significant aspects of COVID-19, including the epidemiology, biological features, organs failure, and diagnostic techniques.

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Pharmacology,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3